Spots Global Cancer Trial Database for A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma
Official Title: A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma
Study ID: NCT04845139
Interventions
Study Description
Brief Summary: The purpose of this study is to determine whether Nivolumab given intrathecally is effective in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Detailed Description: This is a case study aiming to recruit 1 patient. This study is indicated for relapsed/refractory primary central nervous system lymphoma. Primary objective is to explore the safety.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Jianmin Zhang, Hangzhou, Zhejiang, China
Contact Details
Name: Jianmin Zhang, M.D.
Affiliation: Second Affiliated Hospital, School of Medicine, Zhejiang University, China
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
